Clinical Trials Logo

Clinical Trial Summary

Antimicrobial or antibiotic agents, which are essential to prevent and treat bacterial infectious diseases, have become one of the most widely used drugs in the world. In the European region, the highest rates of antibiotic consumption are reported in Turkey. There is a nearly fivefold difference between Turkey and the lowest consuming countries.

Studies in dentistry evaluate participants according to the basis of predefined criteria. History of antibiotic consumption is one of the most common exclusion criteria for periodontal trials. However, there is still disagreement on how long the effect of systemic antibiotic agents on the oral mucosa and periodontal tissue lasts. It is unclear whether the timing of antibiotic consumption should be an exclusion criterion for genetic damage and histological studies during the selection of healthy participants.

Periodontal status of participants in study groups is described as with or without periodontitis in many studies, because of the lack of clear definitions of periodontal health and gingivitis. It should be recognized that even the lack of visual signs of inflammation, some mild histopathological changes can be seen in the periodontium. Consequently, for the real diagnosis of the clinically healthy periodontium, clinical findings should be supported and confirmed with histological results.

Micronuclei (Mn) are observed as abnormal nuclear structures and indicators of chromosomal level DNA damage. The oral mucosa epithelium is an immunologic barrier and affected by chemical factors such as antibiotic consumption. The Mn test to exfoliated epithelial cells from the oral cavity is utilized as a non-invasive diagnostic technique for monitoring the status of oral health. To our knowledge, no studies have been conducted on the comparison of the impacts of the timing of antibiotic consumption on human periodontal tissues and oral smear samples. The present study is undertaken to determine whether the different timing of antibiotic (amoxicillin) therapy has effects on the histopathology of gingiva and genetic damage of exfoliated cells from oral mucosa in healthy participants.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04172207
Study type Observational
Source Istanbul Medipol University Hospital
Contact
Status Completed
Phase
Start date October 15, 2018
Completion date September 15, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05846399 - CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE) Phase 4
Completed NCT03349567 - Improving Antimicrobial-Prescribing in Emergency Departments N/A
Completed NCT05261152 - S. Boulardii in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adults With Respiratory Tract Infections Phase 4
Terminated NCT03089697 - Phase IIa Clinical Study of N-Rephasin® SAL200 Phase 2
Completed NCT03037112 - Resetting the Default: Improving Provider-patient Communication to Reduce Antibiotic Misuse N/A
Recruiting NCT03440216 - Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units N/A
Completed NCT03408457 - Influence of Perioperative Fluid Balance on Serum Concentrations of Antibiotics and Surgical Site Infections
Completed NCT04872400 - Acute Application of Antibiotic Powder in Open Fracture Wounds Phase 4
Completed NCT03114358 - Carbapenems De-escalation as Antimicrobial Stewardship N/A
Completed NCT03245879 - Antibiotic Stewardship in Small Hospitals N/A
Recruiting NCT05925309 - Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy N/A
Completed NCT03098485 - Healthy Patients & Effect of Antibiotics N/A
Completed NCT00272155 - An Intervention to Reduce Inappropriate Prescriptions of Antibiotics for Respiratory Infections in General Practice Phase 1/Phase 2
Completed NCT03280147 - 7 Days Versus 14 Days of Antibiotics for Neonatal Sepsis Phase 3
Completed NCT04713436 - The Effects of Antibiotic Combinations on Stem Cells
Completed NCT03446053 - A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers Phase 1
Completed NCT04210713 - Neuroimmune Dysfunction in Alcohol Use Disorder Phase 1
Recruiting NCT05132829 - Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial Phase 4
Recruiting NCT05284318 - Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI.
Completed NCT01855048 - A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers Phase 1